Table 1 Baseline demographic data and clinical characteristics of patients included in the study
From: The effect of dobutamine in sepsis: a propensity score matched analysis
Covariate | Original patients (before matching) | Missing data (%) | ||
|---|---|---|---|---|
Non-dobutamine group (N = 2165) | Dobutamine group (N = 121) | P value | ||
Age (years) | 66.63 ± 17.06 | 68.57 ± 16.44 | 0.222 | 0.0 |
Gender (Male), n (%) | 1208 (55.8%) | 74 (61.2%) | 0.248 | 0.0 |
Height (cm) | 168.76 ± 11.00 | 168.61 ± 9.68 | 0.883 | 0.0 |
Weight (kg) | 82.65 ± 27.00 | 83.26 ± 21.95 | 0.808 | 0.0 |
BMI (kg/m [2]) | 29.00 ± 9.00 | 29.13 ± 6.72 | 0.871 | 0.0 |
Temperature (℃) | 37.71 ± 1.04 | 37.87 ± 1.11 | 0.108 | 0.4 |
MAP (mmHg) | 51.63 ± 14.01 | 46.44 ± 15.51 | 0.000 | 0.0 |
HR (beats min−1) | 112.71 ± 22.97 | 118.60 ± 23.46 | 0.006 | 0.0 |
RR (min−1) | 30.23 ± 7.11 | 31.78 ± 8.00 | 0.020 | 0.0 |
SOFA score | 7.22 ± 4.00 | 9.91 ± 3.73 | 0.000 | 0.0 |
SOFA-cardiovascular score | 2.26 ± 1.45 | 3.23 ± 1.20 | 0.000 | 0.0 |
SAPS-I score | 21.46 ± 5.68 | 24.86 ± 5.64 | 0.000 | 0.0 |
SAPS-II score | 46.76 ± 16.66 | 56.59 ± 14.83 | 0.000 | 0.0 |
ECI | 10.36 ± 7.91 | 11.06 ± 7.92 | 0.342 | 0.0 |
Norepinephrine dose (mg) | 58.30 ± 82.56 | 79.89 ± 96.44 | 0.004 | 0.0 |
Norepinephrine use | 1269 (58.6%) | 110 (90.9%) | 0.000 | 0.0 |
Urine volume (ml, 1st day) | 1565.61 ± 1333.18 | 1083.63 ± 1005.80 | 0.000 | 1.0 |
Input volume (ml, 1st day) | 8209.26 ± 6142.67 | 9471.47 ± 7166.17 | 0.069 | 4.3 |
Microbiology, n (%) | ||||
 Positive (%) | 1719 (79.4%) | 99 (81.8%) | 0.521 | 0.0 |
 Negative | 446 (20.6%) | 22 (18.2%) | ||
Interventions, n (%) | ||||
 Renal replacement use (1st day) | 170 (7.9%) | 15 (12.4%) | 0.074 | 0.0 |
 Mechanical ventilation use (1st day) | 1128 (52.1%) | 95 (78.5%) | 0.000 | 0.0 |
Comorbidities, n (%) | ||||
 Congestive heart failure | 780 (36.0%) | 75 (62.0%) | 0.000 | 0.0 |
 Pulmonary circulation disease | 168 (7.8%) | 10 (8.3%) | 0.840 | 0.0 |
 Renal failure | 469 (21.7%) | 23 (19.0%) | 0.489 | 0.0 |
 Diabetes | 676 (31.2%) | 44 (36.4%) | 0.236 | 0.0 |
 COPD | 496 (22.9%) | 33 (27.3%) | 0.268 | 0.0 |
 Coagulopathy | 614 (28.4%) | 53 (43.8%) | 0.000 | 0.0 |
 Fluid electrolyte disorder | 1204 (55.6%) | 66 (54.5%) | 0.818 | 0.0 |
Admission type, n (%) | ||||
 Emergency | 2106 (97.3%) | 113 (93.4%) | 0.014 | 0.0 |
 Elective | 59 (2.7%) | 8 (6.6%) | 0.0 | |
Sepsis type, n (%) | ||||
 Sepsis | 451 (20.8%) | 7 (5.8%) | 0.000 | 0.0 |
 Severe sepsis | 896 (41.4%) | 50 (41.3%) | 0.0 | |
 Septic shock | 818 (37.8%) | 64 (52.9%) | 0.0 | |
Laboratory Tests | ||||
 Lactate (mmol/L) | 2.59 ± 2.19 | 3.50 ± 2.86 | 0.001 | 48.4 |
 Glucose-min | 106.90 ± 38.77 | 108.06 ± 48.17 | 0.753 | 0.5 |
 Glucose-max | 190.70 ± 94.38 | 227.50 ± 93.32 | 0.000 | 0.5 |